Claturafenib
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Claturafenib
- Molecular weight
- 490.32
- Structure (SMILES)
- Cn1cnc2ccc(Nc3c(F)ccc(NS(=O)(=O)N4CC(F)C4)c3Cl)c(Cl)c2c1=O
- arry 440
- ARRY-440
- arry440
- ARRY440
- claturafenib
- Claturafenib
- claturafenib [INN]
- CLATURAFENIB [USAN]
- claturafenib inn
- claturafenib usan
- pf 07799933
- pf 07799933 who dd
- Pf-07799933
- PF-07799933
- PF-07799933 [WHO-DD]
- pf07799933
- PF07799933
- CAS registry numbers
- 2754408-94-9
- ChEMBL ID
- CHEMBL6068425
- InChIKey
- SHENFUUACGRLOZ-UHFFFAOYSA-N
- PubChem compound IDs
- 165150001
- FDA ingredient codes (UNII)
- PC35M52J8T
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- claturafenib
- Type
- Synthetic organic
- Drug name stem
- -rafenib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- B-Raf proto-oncogene, serine/threonine kinase
- Gene symbol
- BRAF
- Protein identifier
- P15056
- Median affinity
- 7.46
- Affinity units
- pEC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 96.33
- Calculated partition coefficient (ALogP)
- 3.43
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 31
- Molecular formula
- C18H15Cl2F2N5O3S
- Monoisotopic mass
- 489.0240722
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (3)
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544
In development for (1)
- Neoplasm Phase 1